4D Molecular Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Return on Equity (ROE) Growth & History (FDMT)
4D Molecular Therapeutics's return on equity was −27.57% for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −27.57% | +11.74 pp |
| 2024 | 2024-12-31 | −39.31% | −1.91 pp |
| 2023 | 2023-12-31 | −37.40% | +1.65 pp |
| 2022 | 2022-12-31 | −39.06% | −14.27 pp |
| 2021 | 2021-12-31 | −24.78% | +37.03 pp |
| 2020 | 2020-12-31 | −61.82% | — |
4D Molecular Therapeutics quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −16.97% | −4.70 pp |
| Q1 2026 | 2026-03-31 | −14.36% | −4.58 pp |
| Q4 2025 | 2025-12-31 | 4.44% | +13.78 pp |
| Q3 2025 | 2025-09-30 | −14.40% | −6.72 pp |
| Q2 2025 | 2025-06-30 | −12.27% | −6.39 pp |
| Q1 2025 | 2025-03-31 | −9.79% | −2.65 pp |
| Q4 2024 | 2024-12-31 | −9.34% | +0.78 pp |
| Q3 2024 | 2024-09-30 | −7.68% | −4.55 pp |
| Q2 2024 | 2024-06-30 | −5.88% | +5.01 pp |
| Q1 2024 | 2024-03-31 | −7.13% | +5.62 pp |
| Q4 2023 | 2023-12-31 | −10.12% | +1.22 pp |
| Q3 2023 | 2023-09-30 | −3.13% | +6.68 pp |
| Q2 2023 | 2023-06-30 | −10.89% | −1.01 pp |
| Q1 2023 | 2023-03-31 | −12.75% | −4.19 pp |
| Q4 2022 | 2022-12-31 | −11.34% | −2.11 pp |
| Q3 2022 | 2022-09-30 | −9.81% | −0.24 pp |
| Q2 2022 | 2022-06-30 | −9.88% | −6.74 pp |
| Q1 2022 | 2022-03-31 | −8.56% | −1.98 pp |
| Q4 2021 | 2021-12-31 | −9.23% | +13.17 pp |
| Q3 2021 | 2021-09-30 | −9.57% | — |
| Q2 2021 | 2021-06-30 | −3.14% | — |
| Q1 2021 | 2021-03-31 | −6.58% | — |
| Q4 2020 | 2020-12-31 | −22.40% | — |
4D Molecular Therapeutics return on equity trends
Over the last five fiscal years, 4D Molecular Therapeutics's return on equity increased from −61.82% to −27.57%, a change of +34.25 percentage points. The latest reported quarter, Q2 2026, shows −16.97%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗